Century Therapeutics (IPSC) Competitors

$2.27 +0.02 (+0.89%)

Closing price 04:00 PM Eastern

Extended Trading

$2.24 -0.03 (-1.32%)

As of 07:56 PM Eastern

IPSC vs. ARDX, TSHA, IOVA, PVLA, and DMRA

Should you buy Century Therapeutics stock or one of its competitors? MarketBeat compares Century Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Century Therapeutics include Ardelyx (ARDX), Taysha Gene Therapies (TSHA), Iovance Biotherapeutics (IOVA), Palvella Therapeutics (PVLA), and Damora Therapeutics, Inc. Common Stock (DMRA). These companies are all part of the "pharmaceutical products" industry.

How does Century Therapeutics compare to Ardelyx?

Century Therapeutics (NASDAQ:IPSC) and Ardelyx (NASDAQ:ARDX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, profitability, dividends, analyst recommendations, valuation, institutional ownership and media sentiment.

50.2% of Century Therapeutics shares are owned by institutional investors. Comparatively, 58.9% of Ardelyx shares are owned by institutional investors. 4.4% of Century Therapeutics shares are owned by insiders. Comparatively, 5.3% of Ardelyx shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Century Therapeutics had 6 more articles in the media than Ardelyx. MarketBeat recorded 10 mentions for Century Therapeutics and 4 mentions for Ardelyx. Century Therapeutics' average media sentiment score of 0.72 beat Ardelyx's score of 0.26 indicating that Century Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Century Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Ardelyx	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Century Therapeutics has higher earnings, but lower revenue than Ardelyx. Ardelyx is trading at a lower price-to-earnings ratio than Century Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Century Therapeutics	$109.16M	3.75	-$9.58M	-$1.14	N/A
Ardelyx	$407.32M	3.85	-$61.60M	-$0.23	N/A

Century Therapeutics presently has a consensus price target of $3.67, indicating a potential upside of 61.53%. Ardelyx has a consensus price target of $15.70, indicating a potential upside of 147.24%. Given Ardelyx's stronger consensus rating and higher possible upside, analysts clearly believe Ardelyx is more favorable than Century Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Century Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Ardelyx	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90

Century Therapeutics has a net margin of 0.00% compared to Ardelyx's net margin of -13.58%. Ardelyx's return on equity of -38.11% beat Century Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Century Therapeutics	N/A	-49.89%	-37.42%
Ardelyx	-13.58%	-38.11%	-11.85%

Century Therapeutics has a beta of 1.55, meaning that its share price is 55% more volatile than the broader market. Comparatively, Ardelyx has a beta of 0.62, meaning that its share price is 38% less volatile than the broader market.

Summary

Ardelyx beats Century Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Century Therapeutics compare to Taysha Gene Therapies?

Century Therapeutics (NASDAQ:IPSC) and Taysha Gene Therapies (NASDAQ:TSHA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, earnings, media sentiment, institutional ownership, profitability and dividends.

Century Therapeutics has a beta of 1.55, meaning that its stock price is 55% more volatile than the broader market. Comparatively, Taysha Gene Therapies has a beta of 1.25, meaning that its stock price is 25% more volatile than the broader market.

Century Therapeutics presently has a consensus price target of $3.67, suggesting a potential upside of 61.53%. Taysha Gene Therapies has a consensus price target of $11.64, suggesting a potential upside of 110.04%. Given Taysha Gene Therapies' stronger consensus rating and higher possible upside, analysts clearly believe Taysha Gene Therapies is more favorable than Century Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Century Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Taysha Gene Therapies	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00

Century Therapeutics has higher revenue and earnings than Taysha Gene Therapies. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than Century Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Century Therapeutics	$109.16M	3.75	-$9.58M	-$1.14	N/A
Taysha Gene Therapies	$9.77M	162.95	-$109M	-$0.38	N/A

Century Therapeutics' return on equity of -49.89% beat Taysha Gene Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Century Therapeutics	N/A	-49.89%	-37.42%
Taysha Gene Therapies	N/A	-56.07%	-40.16%

50.2% of Century Therapeutics shares are held by institutional investors. Comparatively, 77.7% of Taysha Gene Therapies shares are held by institutional investors. 4.4% of Century Therapeutics shares are held by company insiders. Comparatively, 3.8% of Taysha Gene Therapies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Century Therapeutics had 9 more articles in the media than Taysha Gene Therapies. MarketBeat recorded 10 mentions for Century Therapeutics and 1 mentions for Taysha Gene Therapies. Century Therapeutics' average media sentiment score of 0.72 beat Taysha Gene Therapies' score of 0.00 indicating that Century Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Century Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Taysha Gene Therapies	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Century Therapeutics beats Taysha Gene Therapies on 8 of the 15 factors compared between the two stocks.

How does Century Therapeutics compare to Iovance Biotherapeutics?

Iovance Biotherapeutics (NASDAQ:IOVA) and Century Therapeutics (NASDAQ:IPSC) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, earnings, dividends, profitability, institutional ownership, risk, analyst recommendations and valuation.

Iovance Biotherapeutics presently has a consensus target price of $8.43, suggesting a potential upside of 127.80%. Century Therapeutics has a consensus target price of $3.67, suggesting a potential upside of 61.53%. Given Iovance Biotherapeutics' higher probable upside, analysts plainly believe Iovance Biotherapeutics is more favorable than Century Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Iovance Biotherapeutics	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.30
Century Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Century Therapeutics has lower revenue, but higher earnings than Iovance Biotherapeutics. Iovance Biotherapeutics is trading at a lower price-to-earnings ratio than Century Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Iovance Biotherapeutics	$263.50M	6.27	-$390.98M	-$0.95	N/A
Century Therapeutics	$109.16M	3.75	-$9.58M	-$1.14	N/A

77.0% of Iovance Biotherapeutics shares are owned by institutional investors. Comparatively, 50.2% of Century Therapeutics shares are owned by institutional investors. 7.8% of Iovance Biotherapeutics shares are owned by insiders. Comparatively, 4.4% of Century Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Century Therapeutics has a net margin of 0.00% compared to Iovance Biotherapeutics' net margin of -123.92%. Century Therapeutics' return on equity of -49.89% beat Iovance Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Iovance Biotherapeutics	-123.92%	-50.17%	-38.77%
Century Therapeutics	N/A	-49.89%	-37.42%

Iovance Biotherapeutics has a beta of 0.69, suggesting that its stock price is 31% less volatile than the broader market. Comparatively, Century Therapeutics has a beta of 1.55, suggesting that its stock price is 55% more volatile than the broader market.

In the previous week, Century Therapeutics had 8 more articles in the media than Iovance Biotherapeutics. MarketBeat recorded 10 mentions for Century Therapeutics and 2 mentions for Iovance Biotherapeutics. Century Therapeutics' average media sentiment score of 0.72 beat Iovance Biotherapeutics' score of 0.00 indicating that Century Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Iovance Biotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Century Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Century Therapeutics beats Iovance Biotherapeutics on 8 of the 15 factors compared between the two stocks.

How does Century Therapeutics compare to Palvella Therapeutics?

Palvella Therapeutics (NASDAQ:PVLA) and Century Therapeutics (NASDAQ:IPSC) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

Palvella Therapeutics presently has a consensus price target of $199.53, indicating a potential upside of 72.13%. Century Therapeutics has a consensus price target of $3.67, indicating a potential upside of 61.53%. Given Palvella Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Palvella Therapeutics is more favorable than Century Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Palvella Therapeutics	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.94
Century Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Century Therapeutics' return on equity of -49.89% beat Palvella Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Palvella Therapeutics	N/A	-56.87%	-42.50%
Century Therapeutics	N/A	-49.89%	-37.42%

In the previous week, Palvella Therapeutics had 1 more articles in the media than Century Therapeutics. MarketBeat recorded 11 mentions for Palvella Therapeutics and 10 mentions for Century Therapeutics. Century Therapeutics' average media sentiment score of 0.72 beat Palvella Therapeutics' score of 0.29 indicating that Century Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Palvella Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Century Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Century Therapeutics has higher revenue and earnings than Palvella Therapeutics. Palvella Therapeutics is trading at a lower price-to-earnings ratio than Century Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Palvella Therapeutics	$42.81M	38.83	-$41.72M	-$4.17	N/A
Century Therapeutics	$109.16M	3.75	-$9.58M	-$1.14	N/A

Palvella Therapeutics has a beta of -0.13, indicating that its stock price is 113% less volatile than the broader market. Comparatively, Century Therapeutics has a beta of 1.55, indicating that its stock price is 55% more volatile than the broader market.

40.1% of Palvella Therapeutics shares are owned by institutional investors. Comparatively, 50.2% of Century Therapeutics shares are owned by institutional investors. 20.5% of Palvella Therapeutics shares are owned by company insiders. Comparatively, 4.4% of Century Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Century Therapeutics beats Palvella Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Century Therapeutics compare to Damora Therapeutics, Inc. Common Stock?

Century Therapeutics (NASDAQ:IPSC) and Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings, valuation and media sentiment.

50.2% of Century Therapeutics shares are held by institutional investors. Comparatively, 14.2% of Damora Therapeutics, Inc. Common Stock shares are held by institutional investors. 4.4% of Century Therapeutics shares are held by insiders. Comparatively, 0.4% of Damora Therapeutics, Inc. Common Stock shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Century Therapeutics has higher revenue and earnings than Damora Therapeutics, Inc. Common Stock. Damora Therapeutics, Inc. Common Stock is trading at a lower price-to-earnings ratio than Century Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Century Therapeutics	$109.16M	3.75	-$9.58M	-$1.14	N/A
Damora Therapeutics, Inc. Common Stock	N/A	N/A	-$209.84M	-$6.88	N/A

Century Therapeutics has a beta of 1.55, meaning that its share price is 55% more volatile than the broader market. Comparatively, Damora Therapeutics, Inc. Common Stock has a beta of 1.5, meaning that its share price is 50% more volatile than the broader market.

Century Therapeutics' return on equity of -49.89% beat Damora Therapeutics, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Century Therapeutics	N/A	-49.89%	-37.42%
Damora Therapeutics, Inc. Common Stock	N/A	-428.30%	-114.62%

In the previous week, Century Therapeutics had 9 more articles in the media than Damora Therapeutics, Inc. Common Stock. MarketBeat recorded 10 mentions for Century Therapeutics and 1 mentions for Damora Therapeutics, Inc. Common Stock. Century Therapeutics' average media sentiment score of 0.72 beat Damora Therapeutics, Inc. Common Stock's score of 0.00 indicating that Century Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Century Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Damora Therapeutics, Inc. Common Stock	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Century Therapeutics currently has a consensus target price of $3.67, indicating a potential upside of 61.53%. Damora Therapeutics, Inc. Common Stock has a consensus target price of $43.40, indicating a potential upside of 74.58%. Given Damora Therapeutics, Inc. Common Stock's stronger consensus rating and higher probable upside, analysts clearly believe Damora Therapeutics, Inc. Common Stock is more favorable than Century Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Century Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Damora Therapeutics, Inc. Common Stock	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88

Summary

Century Therapeutics beats Damora Therapeutics, Inc. Common Stock on 10 of the 14 factors compared between the two stocks.

Get Century Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IPSC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IPSC vs. The Competition

Export

Metric	Century Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$405.80M	$3.02B	$6.34B	$12.29B
Dividend Yield	N/A	1.97%	2.80%	5.36%
P/E Ratio	N/A	17.78	20.94	25.46
Price / Sales	3.75	251.59	521.00	73.83
Price / Cash	169.17	56.99	43.18	55.00
Price / Book	1.54	4.58	9.98	7.00
Net Income	-$9.58M	$74.99M	$3.55B	$335.16M
7 Day Performance	-4.62%	-2.36%	0.42%	-0.29%
1 Month Performance	-1.30%	-4.13%	-0.05%	1.15%
1 Year Performance	291.65%	36.31%	35.06%	34.79%

Century Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IPSC Century Therapeutics	2.4476 of 5 stars	$2.27 +0.9%	$3.67 +61.5%	+275.0%	$405.80M	$109.16M	N/A	170	Analyst Revision
ARDX Ardelyx	3.4523 of 5 stars	$6.22 +1.7%	$15.70 +152.6%	+50.0%	$1.53B	$407.32M	N/A	90	Positive News
TSHA Taysha Gene Therapies	2.4503 of 5 stars	$5.32 -2.5%	$11.64 +118.9%	+87.4%	$1.53B	$9.77M	N/A	180	Gap Down
IOVA Iovance Biotherapeutics	2.1089 of 5 stars	$3.42 +0.7%	$8.43 +146.8%	+85.3%	$1.52B	$263.50M	N/A	500
PVLA Palvella Therapeutics	3.4465 of 5 stars	$106.20 +1.1%	$199.53 +87.9%	+397.2%	$1.52B	N/A	N/A	N/A	News Coverage Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IPSC) was last updated on 5/21/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Century Therapeutics (IPSC) Competitors

IPSC vs. ARDX, TSHA, IOVA, PVLA, and DMRA

How does Century Therapeutics compare to Ardelyx?

Summary

How does Century Therapeutics compare to Taysha Gene Therapies?

Summary

How does Century Therapeutics compare to Iovance Biotherapeutics?

Summary

How does Century Therapeutics compare to Palvella Therapeutics?

Summary

How does Century Therapeutics compare to Damora Therapeutics, Inc. Common Stock?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IPSC vs. The Competition

Century Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Century Therapeutics (IPSC) Competitors

IPSC vs. ARDX, TSHA, IOVA, PVLA, and DMRA

How does Century Therapeutics compare to Ardelyx?

Do insiders and institutionals have more ownership in IPSC or ARDX?

Does the media prefer IPSC or ARDX?

Which has stronger earnings & valuation, IPSC or ARDX?

Do analysts rate IPSC or ARDX?

Is IPSC or ARDX more profitable?

Which has more risk & volatility, IPSC or ARDX?

Summary

How does Century Therapeutics compare to Taysha Gene Therapies?

Which has more risk and volatility, IPSC or TSHA?

Do analysts recommend IPSC or TSHA?

Which has higher earnings & valuation, IPSC or TSHA?

Is IPSC or TSHA more profitable?

Do insiders & institutionals believe in IPSC or TSHA?

Does the media prefer IPSC or TSHA?

Summary

How does Century Therapeutics compare to Iovance Biotherapeutics?

Do analysts recommend IOVA or IPSC?

Which has better earnings & valuation, IOVA or IPSC?

Do insiders and institutionals hold more shares of IOVA or IPSC?

Is IOVA or IPSC more profitable?

Which has more risk & volatility, IOVA or IPSC?

Does the media refer more to IOVA or IPSC?

Summary

How does Century Therapeutics compare to Palvella Therapeutics?

Do analysts recommend PVLA or IPSC?

Is PVLA or IPSC more profitable?

Does the media prefer PVLA or IPSC?

Which has stronger valuation & earnings, PVLA or IPSC?

Which has more risk and volatility, PVLA or IPSC?

Do insiders & institutionals have more ownership in PVLA or IPSC?

Summary

How does Century Therapeutics compare to Damora Therapeutics, Inc. Common Stock?

Do institutionals & insiders have more ownership in IPSC or DMRA?

Which has higher earnings and valuation, IPSC or DMRA?

Which has more risk and volatility, IPSC or DMRA?

Is IPSC or DMRA more profitable?

Does the media refer more to IPSC or DMRA?

Do analysts rate IPSC or DMRA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IPSC vs. The Competition

Century Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools